Lu Si, Xiaoshi Zhang , Sang Joon Shin , Yun Fan , Chia-Chi Lin , Tae Min Kim, Arunee Dechaphunkul , Jedzada Maneechavakajorn , Chi Sing Wong , Palanichamy Ilankumaran, Dung-Yang Lee , Eduard Gasal , Haifu Li, Jun Guo*.Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma,Eur J Cancer,2020 Jun 10;135:31-38

Wei X, Wu D, Li H, et al. The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma,Ann Surg Oncol,2020 Apr 6.

Wei X, Si L, Guo J. ASO Author Reflections: Primary Site Should Be Regarded as One Important Factor for Risk Stratification in Acral Melanoma,Ann Surg Oncol,2020 Apr 4

Si L, Zhang X, Shu Y, et al. A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151),Transl Oncol,2019 Jun;12(6):828-835

Wei X, Mao L, Chi Z, et al. Efficacy evaluation of imatinib for the treatment of melanoma: evidence from a retrospective study,Oncol Res.,2019 Mar 29;27(4):495-501.

Wang X, Kong Y, Chi Z, et al.Primary Malignant Melanoma of the Esophagus: A Retrospective Analysis of Clinical Features, Management, and Survival of 76 patients,Thorac Cancer,2019 Apr;10(4):950-956.

Si L, Zhang X, Xu Z, et al. Vemurafenib in Chinese patients with BRAF(V600) mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study,BMC Cancer,2018.05.3, 18(1): 0~520

X Bai, L L Mao, Z H Chi, X N Sheng, C L Cui, Y Kong, J Dai, X Wang, S M Li, B X Tang, B Lian, L Zhou, X Q Yan, J Guo, L Si.BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma,Neoplasma,2017;64:626-632

Bai X, Kong Y, Chi Z, et al. MAPK pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients: a retrospective study of 2793 cases,Clinical Cancer Research,2017;23(20):6120-6127

Kong Y, Si L#, Li Y, Wu X, Xu X, Dai J, Tang H, Ma M, Chi Z, Sheng X, Cui C, Guo J*. Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.,Clinical Cancer Research,2016;22(4):1018-1027

如何修改住院医师病历 , 指导医师培训 , 第1完成人 , 北京大学肿瘤医院 , 2017.5